Opioid Legislation – The Path Forward for FDA and DEA
December 18, 2018

On December 18, Axinn partner Chad Landmon participated in the FDLI webinar, "Opioid Legislation – The Path Forward for FDA and DEA."

The webinar addressed the tools that The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act provide to FDA and DEA to combat the opioid crisis, real-world impacts of the legislation, and whether more federal action is necessary to alleviate the high rates of opioid overdoses and deaths in the US. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.